Effect of ABCB1 3435C>T transporter gene polymorphism on plasma efavirenz concentration in HIV-1 infected Thai adults

Sahapat Barusrux; Napatrupron Koomdee; Rattanaporn Sukprasong; Weerawat Manosuthi; Monpat Chamnanphon; Apichaya Puangpetch; Chonlaphat Sukasem; Veeranoot Nissapatorn; Maria de Lourdes Pereira

doi:10.4103/1995-7645.284645

ORIGINAL ARTICLE

Year : 2020 | Volume : 13 | Issue : 6 | Page : 266-271

Effect of ABCB1 3435C>T transporter gene polymorphism on plasma efavirenz concentration in HIV-1 infected Thai adults

Sahapat Barusrux¹, Napatrupron Koomdee², Rattanaporn Sukprasong², Weerawat Manosuthi³, Monpat Chamnanphon⁴, Apichaya Puangpetch², Chonlaphat Sukasem², Veeranoot Nissapatorn¹, Maria de Lourdes Pereira⁵
¹ School of Allied Health Sciences and Research Excellence Center for Innovation and Health Products, Walailak University, Nakhon Si Thammarat, Thailand
² Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok; Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center, Ramathibodi Hospital, Thailand
³ Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Thailand
⁴ Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok; Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center, Ramathibodi Hospital; Clinical Pharmacokinetics and Pharmacogenomics Research Unit, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
⁵ CICECO-Aveiro Institute of Materials and Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal

Date of Submission	31-Oct-2019
Date of Decision	19-May-2020
Date of Acceptance	21-May-2020
Date of Web Publication	03-Jun-2020

Correspondence Address:
Napatrupron Koomdee
Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok; Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center, Ramathibodi Hospital
Thailand
Sahapat Barusrux
School of Allied Health Sciences and Research Excellence Center for Innovation and Health Products, Walailak University, Nakhon Si Thammarat
Thailand

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1995-7645.284645

Abstract

Objective: To investigate the influence of ABCB1 polymorphisms on the plasma level of efavirenz in Thai adult cases infected with HIV-1.
Methods: A single nucleotide polymorphism of ABCB1 3435C>T (rs1045642) in the gene encoding ABCB1 was genotyped using real-time PCR-based alleles in 149 HIV-infected Thai adults receiving efavirenz treatment. Plasma concentrations of efavirenz were measured by high-performance liquid chromatography 12 hr after administration. The relationship between plasma efavirenz concentrations and ABCB1 3435C>T polymorphisms was analyzed.
Results: Logistic regression analysis showed no significant predictors of high plasma efavirenz concentration in relation to age, gender, body weight, CD4 count and plasma HIV-1 RNA, blood biochemical parameters, antiretroviral duration or ABCB1 3435C>T polymorphisms, except for height (OR=0.902, 95% CI: 0.835-0.973) (P<0.05). The minor allele frequency of ABCB1 3435C>T was 0.446. The frequency of the heterozygous mutant ABCB1 3435C/ T was 53.02% (n=79), ABCB1 3435T/T homozygous mutant was 18.12% (n=27) and the wild type ABCB1 3435C/C genotype was 28.86% (n=43). The overall median plasma concentration of efavirenz in 149 HIV-infected Thai cases was 2.41 mg/L [IQR: (1.46-4.12) mg/L]. The plasma concentration of efavirenz was higher in cases with ABCB1 3435T/T homozygous mutant [2.73 mg/L, IQR: (2.02-4.19) mg/L] and ABCB1 3435C/T heterozygous mutant [2.29 mg/L, IQR: (1.41-4.28) mg/L] genotypes compared to the wild type ABCB1 3435C/C homozygous [2.1 mg/L, IQR: (1.37-3.53) mg/L]. However, there was no statistically significant difference in the efavirenz concentration between the different genotypes (P>0.05).
Conclusions: There is no statistical significance for a tendency toward higher plasma efavirenz concentration in the ABCB1 3435T/T and ABCB1 3435C/T genotypes. No parameters of physiological characteristics in this study except for height were found to be predictors of high plasma efavirenz concentration in Thai HIV-1 infected cases.

Keywords: Transporter gene; ABCB1 3435C>T; Efavirenz; HIV-1; Thai

How to cite this article:
Barusrux S, Koomdee N, Sukprasong R, Manosuthi W, Chamnanphon M, Puangpetch A, Sukasem C, Nissapatorn V, Pereira Md. Effect of ABCB1 3435C>T transporter gene polymorphism on plasma efavirenz concentration in HIV-1 infected Thai adults. Asian Pac J Trop Med 2020;13:266-71

How to cite this URL:
Barusrux S, Koomdee N, Sukprasong R, Manosuthi W, Chamnanphon M, Puangpetch A, Sukasem C, Nissapatorn V, Pereira Md. Effect of ABCB1 3435C>T transporter gene polymorphism on plasma efavirenz concentration in HIV-1 infected Thai adults. Asian Pac J Trop Med [serial online] 2020 [cited 2023 Mar 29];13:266-71. Available from: https://www.apjtm.org/text.asp?2020/13/6/266/284645

Sahapat Barusrux, Napatrupron Koomdee. These authors contributed equally to this work.

1. Introduction

Human immunodeficiency virus type 1 (HIV-1) infection is a global problem and has affected the Thais in different parts of Thailand^[1]. HIV has been found to be co-infected with other viruses (e.g., hepatitis)^[1],[2]. People with HIV are at an increased risk of cancer, while HIV cases receiving cancer treatment require careful monitoring for potential drug interactions and toxicity, particularly for the prevention of opportunistic infections^[3]. Highly active antiretroviral therapy (HAART) is used to treat HIV-1 infection, lowering the amount of HIV circulating in the blood, thus allowing partial restoration of immune system function. Efavirenz, a non- nucleoside reverse transcriptase inhibitor is used as a HAART for the treatment of HIV-1 infection. Efavirenz has been combined with the popular HIV drug Truvada, which consists of tenofovir and emtricitabine. This combination provides the simple HAART in a single tablet that effectively suppresses HIV replication in most cases, increases medication adherence, and minimizes toxicity^[4]. The preferred therapeutic range for plasma efavirenz concentrations is 1.0-4.0 mg/L^[5]. Below 1 mg/mL, the plasma level has been associated with treatment failure in an efavirenz-based regimen^[6]. The level above 4.0 mg/L has been associated with an increased risk of side effects and central nervous system toxicity^[7],[8]. Many antiretroviral drugs approved by the Food and Drug Administration, including efavirenz, are affected by the multidrug transporter P-glycoprotein (P-gp), encoded by the ABCB1 gene. ABCB1, the 209.6 kb ATP-binding cassette gene family containing 29 exons, located on chromosome 7q21.12, has about 50 members^[9]. Currently, there are more than eight common single nucleotide polymorphisms in the protein-coding region of ABCB1, which are 1236C>T (rs1128503), 2677G/A>T (rs2032582), c.3435C>T (rs1045642), 1659G>C (rs2235012), 781A>G (rs36008564), 239C>A (rs9282565), 1199G>A (rs2229109), and 1795C>T (rs2235036), where multiple alleles have been reported. The ABCB1 1236C>T allele that occurrs in exon 13, does not result in an amino acid changes, but it can affect the expression of ABCB1 through the use of codon^[10]. The ABCB1 2677G>T/A allele results in a change from serine to alanine or threonine at residue 893, but the effect of changes in protein function is uncertain, although it has been associated with virological failure^[11]. The effect of changes in protein function of the ABCB1 1659G>C (a synonymous), ABCB1 781A>G (Ile261val), ABCB1 239C>A (Ala80Glu), ABCB1 1199G>A (Ser400Asn), and ABCB1 1795C>T (Ala599Thr) is also uncertain. The ABCB1 c.3435C>T variant is commonly known to be associated with reduced expression of P-gp^[12]. Previous studies in other ethnic groups on the effect of ABCB1 c.3435C>T polymorphisms on the variability in plasma efavirenz concentrations are still unclear^[13],[14]. However, current data on the association of plasma levels of efavirenz and other genetic markers have been reported in HIV-1 infected Thai adults^[15],[16]. In addition, there are no data reporting this variant of single nucleotide polymorphism in Thai adults infected with HIV-1. This study aims to evaluate the effect of ABCB1 3435C>T polymorphisms on plasma levels of efavirenz in Thai adults infected with HIV-1 and to explore the clinical significance of single nucleotide polymorphisms.

2. Materials and Methods

2.1. Study design and sample size calculation

The sample size of Thai HIV-infected cases was calculated to assure a 95% confidence interval based on the following formula: n=Z²_αpq/d², where the value of the 95% confidence interval (Z_005/2) (two tails) is 1.96. The frequency of ABCB1 c.3435T allele (T=0.37) as previous described was used to calculate in this study^[17]. At least 138 cases were recruited from the sample size calculation with 20% of the of the test allowance error.

2.2. Written informed consent and ethical approval

Written informed consent to participate in the study was provided in accordance with the guidelines of the Declaration of Helsinki 2008. This study was approved by the Ethics Committee of the Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand (EC_590777 No. MURA2016/517).

2.3. Patient samples

A total of one hundred and forty-nine cases of Thai adults infected with HIV-1 being treated with efavirenz at Bamrasnaradura Infectious Diseases Institute, Thailand, were recruited for this study. The inclusion criteria for this study were: 1) All HIV-infected participants, aged 18 years or older, without opportunistic infections, 2) Subjects who firstly received antiretroviral and 3) Subjects who started the triple therapy regimen of tenofovir (300 mg), lamivudine (300 mg) and efavirenz (600 mg). Cases that received concomitant treatment and potentially had affected efavirenz pharmacokinetics were excluded. All subjects took the drug regimen at bedtime. The plasma efavirenz concentration in a mid-dose was determined at 12 wk after the initiation of antiretroviral therapy. A five milliliter of venous blood was collected in a steady state in an EDTA tube before administration and was submitted to the Laboratory for Pharmacogenomics and Personalized Medicine at Ramathibodi Hospital, Mahidol University for the ABCB1 3435C>T (rs1045642) genotyping. Samples were centrifuged at 3 000 rpm for 15 min. The genomic DNA was isolated for genotyping. Steady state plasma samples were stored at -20 °C for 12 hr after administration until further analysis.

2.4. ABCB1 3435C>T genotyping

The ABCB1 3435C>T polymorphism was investigated with HapMap (http://www.hapmap.org) data on Japanese and Han Chinese populations. The 5’ nuclease chain reaction assay of the allele-specific Taqman® MGB probe with the PCR Viia™ 7 system in real time (Applied Biosystems®, CA, USA) was used with predefined ABCB1 3435C>T primers (assay ID: C_7586657_20, rs1045642) as previously described^[17]. A probe was labeled with fluorogenic VIC dye that detects the sequence of allele 1; the second probe was labeled with a fluorogenic FAM dye that detects the sequence of allele 2. Each mixture of 20 μL of PCR contained 4 μL of genomic DNA (5 ng/μL), 10 μL of Taqman® Genotyping Mastermix, 1 μL of allele-specific Taqman® MGB probe and sequence-specific primer kit and 5 μL of DNase-free of H₂O. The thermal cycler program was set up as follows: at 95 °C for 10 min, 50 cycles repeated at 92 °C for 15 sec and 60° C for 90 sec. The allelic discrimination plot was analyzed using Viia™ 7 software (Applied Biosystems^®, CA, USA).

2.5. Measurement of efavirenz plasma levels

The validated isocratic method high-performance liquid chromatography and reverse phase with ultraviolet detection at 245 nm was used to measure the plasma concentration of efavirenz, as previously described^[18]. A total of 300 μL of plasma samples pretreated with acetonitrile were injected into an Agilent 1100 high-performance liquid chromatography machine. An Omnispher C18 analytical column (150.0 mm×4.6 mm ID/particle size 5 μm) (Varian, CA, USA), a Chromquard RP guard column and a mobile phase consisting of 10 mM KH₂PO₄ pH 3.1: acetonitrile (50: 50, v/v) were used. Version 4.1 of ChromQuest Software was used to process the sample’s peak heights. The average accuracy of 102% to 105% and the coefficient of variation <5% were established. The relationship between the plasma efavirenz concentration and the ABCB1 3435C>T polymorphism was analyzed.

2.6. Statistical analysis

All data were entered, edited and analyzed using the SPSS software for Windows (version 16.0; SPSS Chicago, IL). Genotype distributions were tested for the Hardy-Weinberg equilibrium using exact tests under a 95% exemption call rate. The data were summarized using medians and interquartile ranges (IQR) for continuous variables and frequencies and proportions for categorical variables. The relationship between the plasma efavirenz concentration and genetic polymorphism was assessed by the Kruskal-Wallis test. The Mann-Whitney U-test was used to compare efavirenz concentrations between two genotypes. Furthermore, the association between factors related to HIV infection (age, sex, duration of HIV infection, history of treatment, CD4 count, plasma HIV-1 RNA) and efavirenz concentration was analyzed using the logistic regression model (cases were divided into a plasma efavirenz concentration >4 mg/L and ≤4 mg/L). Statistical significance was defined as P value <0.05.

3. Results

3.1. Efavirenz plasma concentration in HIV-infected Thai adults

The characteristics of 149 HIV-1 infected cases are shown in [Table 1]. The overall average plasma efavirenz concentration 12 hr after administration was 2.41 mg/L (IQR 1.46-4.12 mg/L). There were 100 cases (67.11%) in the therapeutic range (1 to 4 mg/L). There was a large inter-individual variation in plasma levels of efavirenz in 49 cases (32.89%), ranging from <1 mg/mL (efficacy cut-off value) in 11 cases (7.38%) to >4 mg/L (toxicity cut-off value) in 38 cases (25.50%).

Table 1: Characteristics of HIV-1 infected cases enrolled in this study (n=149)

Click here to view

3.2. ABCB1 3435C>T allele frequency and relationship between efavirenz plasma concentration in HIV-infected Thai adults

This study found that the frequency of the heterozygous mutant C/T genotype was 53.02% (n=79), ABCB1 3435T/T or homozygous mutant T/T genotype was 18.12% (n=27) and the wild type ABCB1 3435C/C genotype was 28.86% (n=43). The ABCB1 3435C>T polymorphism was subsequently analyzed under the Hardy- Weinberg equilibrium. The frequency of the minor “T” allele of ABCB1 3435C>T was 0.446. The median plasma concentration of efavirenz in Thai HIV-infected cases with ABCB1 3435T/T was 2.73 mg/L (IQR 2.02-4.19 mg/L), ABCB1 3435C/T genotype was 2.29 mg/L (IQR 1.41-4.28 mg/L) and ABCB1 3435C/C wild type was 2.10 mg/L (IQR 1.37-3.53 mg/L). There was no statistical significance in the efavirenz concentration between the different genotypes (P>0.05).

3.3. The association of multiple factors and plasma efavirenz concentration

The logistic regression analysis showed that there was no association of plasma efavirenz concentration with any parameter of physiological characteristics, such as age, gender, body weight, CD4 count and plasma HIV-1 RNA, blood biochemical parameters, duration of HIV infection or ABCB1 3435C>T polymorphisms. Treatment history, except for height, which was considered as a predictor of high plasma efavirenz concentration (OR=0.902, 95% CI: 0.835-0.973) in Thai HIV-1 infected cases, with significant difference (P<0.05) [Table 2].

Table 2: Predictors of high plasma efavirenz concentration in 149 Thai HIV-infected cases.

Click here to view

4. Discussion

Our report demonstrated the high frequency of ABCB1 3435T allele in HIV-1 infected Thai adults. The allele is 53.02% of ABCB1 3435C/T heterozygous, 18.12% of ABCB1 3435T/T homozygous and 28.86% of homozygous wild type ABCB1 3435C/C. The distribution of the ABCB1 3435C>T polymorphism in this study seems to be smaller than other groups previously reported, such as 49.0% of Japanese cases^[20], 46.6%-54.0% of Chinese cases^[21],[22] and 63.2%- 64.0% of Indian cases^[23],[24], 54.9% of Caucasian cases^[25], and 84.0% in Maasai^[26]. However, the distribution is greater than some other groups, such as 11.0%-21.0% of African cases^{[19],[21],[25]} and 37.3% of Taiwanese cases^[27]. Genetic variation in the ABCB1 gene is known to alter mRNA stability or splicing activity^[28]. ABCB1 3435C>T difference of polymorphism in the mRNA levels of the P-gp messenger^[29], synonymous at 1, 145th residue with the reduction in the expression of the P-gp^[12],[30]. The penetration of the drug in the target cells was observed in the alteration of the expression of P-gp and its function. Then the difference in single nucleotide polymorphism in ABCB1 3435C>T could impact the response to antiretroviral therapy in different populations with variability in plasma efavirenz concentration^{[12],[13],[14]}. We observed that the efavirenz plasma concentration in the trend of the ABCB1 3435T/T [2.73 mg/L, IQR (2.02-4.19) mg/L] and ABCB1 3435C>T [2.29 mg/L, IQR (1.41-4.28) mg/L] were superior to the homozygous wild type ABCB1 3435C/C [2.10 mg/L, IQR (1.37-3.53) mg/L]. Although the findings tend to suggest that ABCB1 3435C>T is probably considered the predictive marker of efavirenz outcomes, but there was no statistically significant difference (P>0.05). Besides, our results are previous reports of lower concentrations of nelfinavir and efavirenz associated with the ABCB1 3435T/T polymorphism^[12],[24], and data from 126 HIV infected cases in South India with the highest values of plasma efavirenz concentration in the wild type ABCB1 3435C/C genotype [(5.22±5.32) mg/L], followed by ABCB1 3435C>T [(3.5±1.83) mg/L] and ABCB1 3435T/T [(2.48±1.29) mg/L]^[24]. The data revealed that inter-individual variations in plasma efavirenz concentrations may be due to an indirect effect of genetic variations in the ABCB1 gene. Thus, further studies with larger sample are needed to verify the benefits of treatment in HIV-infected patients in the future.

The other parameters of physiological characteristics of this study, such as age, gender, body weight, CD4 count and plasma HIV-1 RNA, biochemical parameters in the blood, duration of HIV infection, or treatment history, showed no significant association with plasma efavirenz concentration in the cases of Thai HIV- infected (P>0.05), except for height (OR=0.902, 95% CI: 0.835-0.973) (P<0.05).

In conclusion, although our results among Thai HIV-1 treated with efavirenz demonstrated a tendency towards a higher plasma concentration of efavirenz in cases with the ABCB1 3435T/T and ABCB1 3435C>T genotypes, but there is no significant statistic with the wild type ABCB1 3435C/C. All parameters of physiological characteristics in this study, except height were not found to be predictors of high plasma efavirenz concentration in Thai HIV-1 infected cases. Further studies with a larger scale of sample sizes are recommended for verification.

Conflict of interest statement

We declared that we have no conflict of interest.

Acknowledgments

This work was supported by Mahidol University, Thailand Research Fund, Thailand Office of the Higher Education Commission under New Researchers Grant (MRG 5480136), the project CICECO- Aveiro Institute of Materials, national funds through the FCT/ MCTES (FCT Ref. UID/CTM/50011/2019) and Rachadapisek Sompote Fund for Postdoctoral Fellowship, Chulalongkorn University. We are grateful to the Institute of Infectious Diseases of Bamrasnaradura, the Ministry of Public Health, Thailand and all participants who contributed to the study.

Authors’ contributions

S.B and C.S. developed the concepts. S.B., N.K., R.S., M.C. and A.P. performed the analytical experiment. S.B., N.K., R.S., M.C., W.M. and A.P. performed the data curation. S.B. performed the validation and supervised the project. S.B. and N.K. contributed to the first draft version of the manuscript. S.B., V.N., M.C. and M.P. contributed to the final version of the manuscript.[32]

References

1.	Barusrux S, Urwijitaroon Y, Puapairoj C, Romphruk A, Sriwanitchrak P. Association of HCV and Treponema pallidum infection in HIV infected northeastern Thai male blood donors. J Med Assoc Thai 1997; 80(Suppl 1): S106-111.
2.	Iddi S, Minja CA, Silago V, Benjamin A, Mpesha J, Henerico S, et al. High human immunodeficiency virus (HIV) viral load and coinfection with viral hepatitis are associated with liver enzyme abnormalities among HIV seropositive patients on antiretroviral therapy in the lake Victoria zone, Tanzania. AIDS Res Treat 2019; 6375714. doi:10.1155/2019/6375714
3.	McNally GA. HIV and cancer: An overview of AIDS-defining and non- AIDS-defining cancers in patients with HIV. Clin J Oncol Nurs 2019; 23(3): 327-331.
4.	Sebaaly JC, Kelley D. HIV clinical updates: New single-tablet regimens. Ann Pharmacother 2019; 53(1): 82-94.
5.	Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, et al. Efavirenz therapeutic range in HIV-1 treatment-naive participants. Ther Drug Monit 2017, 39(6):596-603.
6.	Homkham N, Cressey TR, Bouazza N, Ingsrisawang L, Techakunakorn P, Mekmullica J, et al. Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children. PLoS One 2019; 14(5): e0216868. doi: 10.1371/journal.pone.0216868
7.	Torgersen J, Bellamy SL, Ratshaa B, Han X, Mosepele M, Zuppa AF, et al. Impact of efavirenz metabolism on loss to care in older HIV+ Africans. Eur J Drug Metab Pharmacokinet 2019; 44(2): 179-187.
8.	Haas DW, Bradford Y, Verma A, Verma SS, Eron JJ, Gulick RM, et al. Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 2018; 28(7): 179-187.
9.	Bodor M, Kelly EJ, Ho RJ. Characterization of the human MDR1 gene. AAPS J 2005; 7(1): E1-5.
10.	Gu W, Zhou T, Ma J, Sun X, Lu Z. The relationship between synonymous codon usage and protein structure in Escherichia coli and Homo sapiens. Biosystems 2004; 73(2): 89-97.
11.	Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, Labbe L, et al. Multilocus genetic interactions and response to efavirenz- containing regimens: An adult AIDS clinical trials group study. Pharmacogenet Genomics 2006; 16(11): 837-845.
12.	Meissner K, Jedlitschky G, Meyer zu Schwabedissen H, Dazert P, Eckel L, Vogelgesang S, et al. Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 2004; 14(6): 381-385.
13.	Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006; 112(2): 457-473.
14.	Heil SG, van der Ende ME, Schenk PW, van der Heiden I, Lindemans J, Burger D, et al. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals. Ther Drug Monit 2012; 34(2): 153-159.
15.	Sukasem C, Chamnanphon M, Koomdee N, Puangpetch A, Santon S, Jantararoungtong T, et al. High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections. Drug Metab Pharmacokinet 2013; 28(5): 391-397.
16.	Sukasem C, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, et al. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. Br J Clin Pharmacol 2012; 74(6): 1005-1012.
17.	Sensorn I, Sirachainan E, Chamnanphon M, Pasomsub E, Trachu N, Supavilai P, et al. Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer cases treated with tamoxifen. Pharmgenomics Pers Med 2013; 6: 93-98.
18.	Sukasem C, Manosuthi W, Koomdee N, Santon S, Jantararoungtong T, Prommas S, et al. Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism. Infection 2014; 42(3): 469474.
19.	Swart M, Ren Y, Smith P, Dandara C. ABCB1 4036A>G and 1236C>T polymorphisms affect plasma efavirenz levels in South African HIV/ AIDS cases. Front Genet 2012; 3: 236.
20.	Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297(3): 1137-1143.
21.	Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: Frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11(3): 217-221.
22.	Balram C, Sharma A, Sivathasan C, Lee EJ. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: Phenotypic-genotypic correlates. Br J Clin Pharmacol 2003; 56(1): 7883.
23.	Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13(2): 89-95.
24.	Bakshi S, Ramachandran G, Ramesh K, Hemanthkumar AK, Anitha S, Padmapriyadarsini C, et al. Study of ABCB1 polymorphism (C3435T) in HIV-1-infected individuals from South India. Br J Clin Pharmacol 2008; 65(5): 791-792.
25.	Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS clinical trials group study. J Infect Dis 2010; 202(5): 717-722.
26.	Ikediobi O, Aouizerat B, Xiao Y, Gandhi M, Gebhardt S, Warnich L. Analysis of pharmacogenetic traits in two distinct South African populations. Hum Genomics 2011; 5(4): 265-282.
27.	Huang MJ, Chen YL, Chang CY, Huang YY, Huang CS. Polymorphisms of the gene encoding multidrug resistance protein 1 in Taiwanese. J Food Drug Anal 2005; 13: 112-117.
28.	Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 2009; 1794(5): 860-871.
29.	Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315(5811): 525-528.
30.	Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund W, et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J2007; 7(1): 56-65.
31.	Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11(4): 293-298.
32.	Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97(7): 3473-3478.